We selected tamoxifen, an anti-estrogen drug used frequently for luminal breast tumors, known to express estrogen receptors and alpelisib an anti-kinase inhibitor used in personalized therapy (Figure 3). This evidence concerns the gene ESR1 and breast neoplasm.